Among patients who had at least a one-point reduction in pain intensity during three weeks of treatment with tapentadol ER, those who continued on a 100 to 250 mg twice-daily dose for an additional 12 weeks experienced significantly better pain control compared to those who switched to a placebo, the study found.
Adverse effects among these patients included nausea (21.1 percent) and vomiting (12.7 percent).
Related Articles on Pain Management:
Study Targets Effective Adolescent Migraine Relief
Athletes’ Higher Pain Tolerance May Pave Way for Pain Management Research
New Treatment Uses IV Injections for Severe Migraines
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
